Trial Profile
A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Lung transplant rejection
- Focus Adverse reactions; Proof of concept
- Sponsors Kamada
- 31 Aug 2021 Status changed from active, no longer recruiting to completed.
- 06 Apr 2019 6 month outcomes presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
- 27 Feb 2019 Planned End Date changed from 1 Mar 2020 to 1 Apr 2019.